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INTRODUCTION
Staphylococcus and Streptococcus sp. are the most common 
pathogens causing a wide range of complications following joint 
replacement procedures.1 These microorganisms grow in biofilms 
attached to the prosthetic implants, which allows them to evade the 
host’s immune response and resist antibiotics.2 As a result, the rate of 
joint failure has been increasing steadily, which prompted research 
into the most optimal approach for treating prosthetic joint infec-
tions. Treatment usually consists of surgery and antibiotics capable 
of penetrating bone and biofilm producing pathogens. In this report, 
we focus on antibiotic therapy in prosthetic joint infections secondary 
to methicillin-resistant Staphylococcus aureus (MRSA). We present 
a case of relapsing MRSA bacteremia associated with development 
of rifampin resistance in a patient with L3-L4 discitis, ischial and 
lumbar osteomyelitis, and psoas abscess.
CASE REPORT
A male in his late 80's presented with sepsis. He was febrile, 
tachycardic, and lethargic. He had a history of left total knee and hip 
replacement five years prior. He also had left femur fractures a year 
prior to presentation and underwent fixation with intramedullary 
rods in the femoral neck and shaft. Physical examination was remark-
able for a deep lumbosacral ulcer. The left knee and hip did not show 
any signs of infection or joint effusion.
Further work-up revealed that the white blood cell count was 
18,000 cells/mm3 and the erythrocyte sedimentation rate was 120 
mm/hr. His urinalysis was positive for nitrites, leucocyte esterase, 
bacteria, and white blood cells. Laboratory testing was otherwise 
unremarkable. His chest x-ray did not reveal any source of infection. 
Magnetic resonance imaging was consistent with right ischial and 
lumbar spine osteomyelitis, L3-L4 discitis, and psoas muscle infec-
tion. The patient was started on vancomycin and cefepime on the first 
day of admission. 
Initial blood cultures were positive for MRSA, with persistent 
growth on two repeat blood cultures drawn 48 hours apart on day 
three and day five of admission. The urine culture did not grow 
any organism. Transesophageal echocardiogram (TEE) was nega-
tive for vegetations. Cefepime was discontinued. Despite treatment 
with broad spectrum antibiotics, the patient was persistently febrile. 
Rifampin was started on day five owing to concerns for hardware 
infection. All culture susceptibilities showed sensitivity to rifampin 
and vancomycin with mean inhibitory concentration (MIC) less than 
0.5 μg/ml and 1 μg/ml, respectively. The last blood culture set drawn 
on day seven had no growth. Of importance, vancomycin trough 
drawn on day five was 9.1 mcg/mL, below therapeutic range. Dose 
was adjusted and trough was adequate on day seven of admission 
(21.4 mcg/ml). A bone scan did not show any uptake in the joints or 
hardware. Since prosthetic joint infection was ruled out, rifampin was 
discontinued. A bone biopsy was not done due to the lack of resources 
at the hospital; therapy was based on blood cultures. 
Upon resolution of symptoms and stability, the patient was dis-
charged to a transitional living center to complete six weeks of 
intravenous vancomycin. The patient presented again two days fol-
lowing his discharge with sepsis, despite compliance with intravenous 
antibiotic therapy. Blood cultures grew MRSA and susceptibilities 
showed resistance to rifampin with mean inhibitory concentration 
greater than 32 μg/ml. The patient did not want to continue intra-
venous antibiotic therapy. He elected to go home with comfort care.
DISCUSSION
Treatment of prosthetic joint infections secondary to MRSA 
usually begins with parenteral vancomycin, a broad-spectrum anti-
biotic that inhibits cell wall formation and oral rifampin that inhibits 
bacterial RNA-polymerase.2-4 No specific guidance exists as to when 
rifampin should be initiated in patients with prosthetic related infec-
tions. Improved outcomes were seen in animals when comparing 
vancomycin vs. vancomycin/rifampin combination; however, the 
investigators did not address when rifampin was started.5 Rifampin 
monotherapy is not recommended due to rapid development of 
resistant strains following mutations in the rpoB gene.6 Despite dual 
antibiotics therapy, treatment failure occurs, causing significant mor-
bidity to the patients and frequent hospital readmissions. 
MRSA as a pathogen is a major risk factor predicting poor outcome 
after treatment.7 Other causes included failure to identify a second 
pathogen, the choice of surgery (debridement antibiotics and implant 
retention, one step or two step exchange), patient dependent risk 
factors such as higher body mass index, cardiac insufficiency, and 
purulence at the site of infection or inability to use vancomycin due 
to chronic kidney disease, and increased risk for nephrotoxicity.8,9
 Important causes of rifampin resistance include monotherapy, 
combination with oral antibiotics with low bioavailability, or narrow 
spectrum antibiotics.6 In this report, an antibiotic-related factor was 
highlighted that might have been overlooked and not accounted for in 
patients with rifampin resistance. In this patient, at the time rifampin 
was given, vancomycin was not within therapeutic levels. There was 
a 48-hour window during which the patient was being treated with 
rifampin only secondary to sub-therapeutic vancomycin levels. This 
might have contributed to rifampin resistance. Perhaps, rifampin only 
should be initiated after a therapeutic vancomycin level has been 
obtained to decrease the risk of resistance. This particular case was 
unique by providing a serendipitous insight into how quickly rifampin 
resistance can develop in vivo despite the patient being treated with 
vancomycin. Initiating vancomycin and rifampin prior to a known 
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adverse event profile of rifampin without the therapeutic benefits 
of this combination secondary to rapid rifampin resistance develop-
ment.
Furthermore, resistance could develop and remain undetected 
in cases where initial clearance of bacteremia occurs with vanco-
mycin. Bacterial heterogeneity may exist within a single bacterial 
population and the patient could have been infected with multiple 
MRSA strains. The predominant strain may have been sensitive to 
rifampin and first detected in blood cultures while the other strain 
differed phenotypically by expressing rifampin resistance. Prior 
to treatment, the inoculum with the rifampin resistance strain 
was not the strain detected in cultures. Based on the outcome 
seen in our patient, treatment during the rifampin-only window 
could have allowed the resistant strain to become predomi-
nant while the sensitive strain was being inhibited or eradicated. 
Coiffier et al.3 suggested that starting treatment initially with van-
comycin only would decrease the bacterial load, which would decrease 
the risk of resistance to rifampin. Lora-Tamayo et al.10 highlighted 
the higher rate of successful treatment of prosthetic joint infection 
following biofilm and inoculum removal during debridement. The 
Infectious Disease Society of America (IDSA) recommends initi-
ating antibiotic therapy in patients with device related infections 
along with surgical debridement.4 However, there was no mention 
of whether antibiotics should be given before or after debride-
ment. It might be safer to attempt decreasing bacterial load with 
vancomycin and surgical debridement prior to initiating rifampin. 
Further research is needed to clarify the optimal sequence of inter-
ventions that would lead to the highest rate of successful treatment.
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